Transcriptomic Analysis of Incisional Hernia Based on High-throughput Sequencing Technology

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06366581

Enrollment

Registered

2024-04-16

Start date

2023-03-01

Completion date

2024-03-01

Last updated

2024-04-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Extracellular Matrix Alteration, Incisional Hernia

Brief summary

This study included patients who underwent surgical treatment for incisional hernia and non-hernia conditions. Surgical specimens were collected for transcriptome sequencing to obtain the gene expression list. Then genes analyzed by Gene Ontology, protein interactions, and signaling pathway enrichment using the expression matrix.

Interventions

DIAGNOSTIC_TESTTranscriptomic analysis

high-throughput sequencing technology

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

1.18 to 75 years 2.diagnosed with incisional hernia 3.normal tumour markers 4.elective surgery patients.

Exclusion criteria

1. patients with vital organ failure (heart liver, lung, kidney and others) 2. malignant tumors not been completely relieved by active treatment, 3. patients who have psychiatric diseases or comprehension disorders. 4. patients with metabolic disease involving connective tissue collagen.

Design outcomes

Primary

Measure	Time frame	Description
the gene expression list	2023.3-2023.9	the gene expression list

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026